Cargando…
Aspirin for primary prevention: Is this the end of the road?
Aspirin is one of the oldest and most commonly used cardiovascular drugs. Despite there being high-quality evidence supporting the use of aspirin for patients with known cardiovascular disease, a definitive consensus regarding its use for patients at risk for cardiovascular disease (and without esta...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620426/ https://www.ncbi.nlm.nih.gov/pubmed/31280821 http://dx.doi.org/10.1016/j.ihj.2019.04.001 |
_version_ | 1783434045336584192 |
---|---|
author | Singal, Aayush Kumar Karthikeyan, Ganesan |
author_facet | Singal, Aayush Kumar Karthikeyan, Ganesan |
author_sort | Singal, Aayush Kumar |
collection | PubMed |
description | Aspirin is one of the oldest and most commonly used cardiovascular drugs. Despite there being high-quality evidence supporting the use of aspirin for patients with known cardiovascular disease, a definitive consensus regarding its use for patients at risk for cardiovascular disease (and without established cardiovascular disease) has never been reached. Many randomized control trials have produced conflicting results, and consequently, society guidelines have issued differring recommendations. Three major trials were published in 2018, which supplement the existing data on aspirin's role in primary prevention and provide further guidance on this contentious issue. This article reviews the history of aspirin through the last two decades, with special emphasis on these new trials. |
format | Online Article Text |
id | pubmed-6620426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-66204262020-03-01 Aspirin for primary prevention: Is this the end of the road? Singal, Aayush Kumar Karthikeyan, Ganesan Indian Heart J Review Article Aspirin is one of the oldest and most commonly used cardiovascular drugs. Despite there being high-quality evidence supporting the use of aspirin for patients with known cardiovascular disease, a definitive consensus regarding its use for patients at risk for cardiovascular disease (and without established cardiovascular disease) has never been reached. Many randomized control trials have produced conflicting results, and consequently, society guidelines have issued differring recommendations. Three major trials were published in 2018, which supplement the existing data on aspirin's role in primary prevention and provide further guidance on this contentious issue. This article reviews the history of aspirin through the last two decades, with special emphasis on these new trials. Elsevier 2019 2019-05-02 /pmc/articles/PMC6620426/ /pubmed/31280821 http://dx.doi.org/10.1016/j.ihj.2019.04.001 Text en © 2019 Cardiological Society of India. Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Singal, Aayush Kumar Karthikeyan, Ganesan Aspirin for primary prevention: Is this the end of the road? |
title | Aspirin for primary prevention: Is this the end of the road? |
title_full | Aspirin for primary prevention: Is this the end of the road? |
title_fullStr | Aspirin for primary prevention: Is this the end of the road? |
title_full_unstemmed | Aspirin for primary prevention: Is this the end of the road? |
title_short | Aspirin for primary prevention: Is this the end of the road? |
title_sort | aspirin for primary prevention: is this the end of the road? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620426/ https://www.ncbi.nlm.nih.gov/pubmed/31280821 http://dx.doi.org/10.1016/j.ihj.2019.04.001 |
work_keys_str_mv | AT singalaayushkumar aspirinforprimarypreventionisthistheendoftheroad AT karthikeyanganesan aspirinforprimarypreventionisthistheendoftheroad |